Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 2/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31238504 | 1.00 | SOS1 (0.54) | SOS1PARP10PARP3POLBCASP6 | |
| SCHEMBL17508183 | 0.85 | PARP10 (0.49) | SOS1PARP10PARP3POLBCASP6 | |
| SCHEMBL14656250 | 0.84 | SOS1 (0.58) | SOS1PARP10PARP3POLBCASP6 | |
| SCHEMBL14667747 | 0.84 | ALDH1A1 (0.46) | SOS1PARP10PARP3POLBCASP6 | |
| SCHEMBL14661923 | 0.84 | POLB (0.50) | SOS1PARP10PARP3POLBCASP6 | |
| SCHEMBL17099389 | 0.84 | MAOA (0.49) | SOS1ALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL9103436 | 0.84 | ALDH1A1 (0.46) | SOS1PARP10PARP3POLBCASP6 | |
| SCHEMBL9904833 | 0.82 | TTR (0.43) | SOS1POLBCASP6ALDH1A1LMNA | |
| SCHEMBL14656252 | 0.81 | SOS1 (0.44) | SOS1POLBCASP6ALDH1A1LMNA | |
| SCHEMBL14663719 | 0.81 | KIF11 (0.64) | SOS1PARP10PARP3POLBCASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0986540-B1 | THE USE OF CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AS SODIUM CHANNEL BLOCKERS | EURO CELTIQUE SA (LU) | 2005-02-16 | — | — | EP | claimed |
| US-6696442-B2 | THERAPY OF DISORDER RESPONSIVE TO THE BLOCKADE OF SODIUM CHANNELS IN A MAMMAL SUFFERING THEREFROM BY ADMINISTERING CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES, WHICH ACT AS BLOCKERS OF SODIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2004-02-24 | — | — | US | claimed |
| US-RE38425-E1 | ANTICONVULSANTS ADMINISTERED ORALLLY | UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES, INC. (CA) | 2004-02-10 | — | — | US | claimed |
| US-20030225080-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | EURO-CELTIQUES S.A. | 2003-12-04 | — | — | US | claimed |
| US-6613803-B1 | Treating, preventing or ameliorating pain | EURO-CELTIQUE S.A. (LU) | 2003-09-02 | — | — | US | claimed |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-12-05 | — | — | US | claimed |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-05-23 | — | — | US | claimed |
| JP-2001526648-A | — | — | 2001-12-18 | — | — | JP | claimed |
| EP-0836591-B1 | SEMICARBAZONES HAVING CNS ACTIVITY AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME | UNIV SASKATCHEWAN (CA) | 2001-09-26 | — | — | EP | claimed |
| EP-0986540-A4 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | COCENSYS INC (US) | 2001-07-11 | — | — | EP | claimed |
| EP-0986540-A1 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | Cocensys, Inc. (US) | 2000-03-22 | — | — | EP | claimed |
| WO-1998047869-A1 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | COCENSYS, INC. (US) | 1998-10-29 | — | — | WO | claimed |
| US-5741818-A | ANTICONVULSANTS | UNIVERSITY OF SASKATCHEWAN (CA) | 1998-04-21 | — | — | US | claimed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-05-23 | — | — | US | disclosed |
| EP-0986540-A4 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | COCENSYS INC (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-0986540-A1 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | Cocensys, Inc. (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998047869-A1 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | COCENSYS, INC. (US) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225080-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, SLC1A1, SOD1 | SOS1 2709/4885PARP10 4626/4885PARP3 3899/4885 |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, SLC1A1, SOD1 | SOS1 2709/4885PARP10 4626/4885PARP3 3899/4885 |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, CBR1, ALDH1A2 | SOS1 2967/4885PARP10 4587/4885PARP3 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.